País: Canadá
Língua: inglês
Origem: Health Canada
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
DOMINION PHARMACAL
N04BC05
PRAMIPEXOLE
1.5MG
TABLET
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 1.5MG
ORAL
100
Prescription
NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS
Active ingredient group (AIG) number: 0152169004; AHFS:
CANCELLED PRE MARKET
2019-05-01
PRODUCT MONOGRAPH PR DOM-PRAMIPEXOLE (Pramipexole Dihydrochloride Monohydrate) Tablets 0.25 mg, 0.5 mg, 1.0 mg, 1.5 mg ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST DOMINION PHARMACAL DATE OF REVISION: 6111 Royalmount Ave., Suite 100 March 21, 2016 Montreal, Quebec H4P 2T4 Submission Control No: 192720 _ _ _Dom-PRAMIPEXOLE Product Monograph_ _Page 2 of 47 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................9 DRUG INTERACTIONS ..................................................................................................14 DOSAGE AND ADMINISTRATION ..............................................................................16 OVERDOSAGE ................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................23 SPECIAL HANDLING INSTRUCTIONS .......................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................23 PART II: SCIENTIFIC INFORMATION ...............................................................................25 PHARMACEUTICAL INFORMATION ..........................................................................25 CLINICAL TRIALS ........................... Leia o documento completo